Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (209)

« Back to Publications

Using a Markov Model and Real-World Evidence to Identify the Most Cost-Effective Cholesterol Treatment Escalation Threshold for the Secondary Prevention of Cardiovascular Disease.

Mariani A. et al, (2025), Appl Health Econ Health Policy, 23, 869 - 883

Association of Daily Steps with Incident Nonalcoholic Fatty Liver Disease: Evidence from the UK Biobank Cohort.

Fulda ES. et al, (2025), Med Sci Sports Exerc, 57, 1905 - 1913

Fenofibrate and progression of retinopathy in adults with diabetes: the randomised placebo-controlled LENS trial

PREISS D. et al, (2025), NIHR Journals Library

The use of fenofibrate in diabetic retinopathy: narrative review

PREISS D. et al, (2025), Journal of Diabetes and its Complications

Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial

Zhou J. et al, (2025), EClinicalMedicine

Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: an economic evaluation based on data from the LENS trial

PREISS D. et al, (2025), Diabetic Medicine

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

EMPA-KIDNEY Collaborative Group . et al, (2025), N Engl J Med, 392, 777 - 787

Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.

Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129

Towards an understanding of the ethics of electronic consent in clinical trials.

Sahan K. et al, (2024), Trials, 25

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial

Mayne K. et al, (2024), Nephrology Dialysis Transplantation

Patient and public involvement and engagement in the ASCEND PLUS Trial: Reflections from the design of a streamlined and decentralised clinical trial

WIJESURENDRA R. et al, (2024), Trials

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial

Mayne K. and HERRINGTON W., (2024), American Society of Nephrology. Clinical Journal

Effect of Fenofibrate on Progression of Diabetic Retinopathy.

Preiss D. et al, (2024), NEJM evidence, EVIDoa2400179 - EVIDoa2400179

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.

Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk . and Cholesterol Treatment Trialists’ (CTT) Collaboration ., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319

Secondary prevention of cardiovascular disease, including cholesterol targets: summary of updated NICE guidance.

Wonderling D. et al, (2024), BMJ, 384

Load More

1
2
3
4
5
6
7
...
»